Clinical Trial Update: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial (BLAST MRD AML-1) evaluates adding pembrolizumab to intensive chemotherapy as frontline therapy for acute myeloid leukemia; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-04